Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma

TARRYTOWN, N.Y. and PARIS, Sept. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation s... Biopharmaceuticals, Oncology Regeneron Pharmaceuticals, Sanofi, cemiplimab, cutaneous squamous cell carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news